Higher Intraoperative MAP Target (≥80 mmHg) Shows Benefit in High-Risk Hypertensive Patients
In high-risk hypertensive patients undergoing major abdominal surgery, targeting an intraoperative MAP ≥80 mmHg reduces major organ dysfunction and acute kidney injury compared to the standard MAP ≥65 mmHg target, though this benefit does not extend to unselected surgical populations.
Evidence in High-Risk Hypertensive Patients
The most recent and highest quality evidence comes from the HISTAP trial 1, a 2026 multicenter randomized trial of 630 hypertensive patients aged ≥60 years undergoing elective major abdominal surgery. This study demonstrated:
- Primary composite outcome (mortality + major organ dysfunction) occurred in 38.1% with MAP ≥80 mmHg versus 48.9% with MAP ≥65 mmHg (RR 0.78,95% CI 0.65-0.93, P=0.006)
- Acute kidney injury was significantly reduced: 23.5% versus 33.7% (P=0.005)
- Mean achieved MAP was 88±9 mmHg in the treatment group versus 77±7 mmHg in controls
This finding is corroborated by an earlier 2017 Chinese trial 2 in 648 elderly hypertensive patients undergoing gastrointestinal surgery, which found that MAP control at 80-95 mmHg resulted in the lowest AKI incidence (6.3%) compared to both lower (65-79 mmHg: 13.5%) and higher (96-110 mmHg: 12.9%) targets.
Evidence in Unselected Surgical Populations
However, three 2026 meta-analyses examining broader surgical populations found no benefit from higher MAP targets:
- A meta-analysis of 15 trials with 15,603 patients 3 showed no reduction in AKI (RR 0.95), acute myocardial injury (RR 1.02), or mortality (RR 1.00) with higher targets
- Another meta-analysis of 9 RCTs with 14,658 patients 4 found no difference in 30-day mortality (RR 1.06), AKI, or myocardial injury
- A third meta-analysis of individualized versus conventional management 5 in 4,017 patients showed no reduction in AKI (RR 0.88) or mortality (RR 0.96)
Delirium Reduction Signal
Both meta-analyses examining delirium found a potential benefit:
- Higher targets reduced postoperative delirium (RR 0.73,95% CI 0.54-0.98) 3, though trial sequential analysis indicated insufficient evidence for firm conclusions
- Individualized management also reduced delirium rates (RR 0.55,95% CI 0.35-0.88) 5
Clinical Algorithm
For high-risk hypertensive patients (age ≥60, chronic hypertension on home therapy, undergoing major abdominal surgery with additional risk factors):
- Target intraoperative MAP ≥80 mmHg
- Use protocolized fluid therapy and continuous hemodynamic monitoring
- This reduces organ dysfunction primarily through prevention of mild-to-moderate AKI
For unselected surgical populations:
- Standard MAP ≥65 mmHg remains appropriate
- Higher targets do not improve major outcomes and may increase vasoactive drug requirements without clear benefit
Critical Caveats
The divergence between HISTAP's positive findings 1 and negative meta-analyses 3, 4, 5 likely reflects patient selection. HISTAP specifically enrolled high-risk hypertensive patients with protocolized care, while meta-analyses included heterogeneous populations where the intervention may have been diluted. The 2017 Chinese trial 2 supports that the "sweet spot" for elderly hypertensive patients is 80-95 mmHg—higher targets (96-110 mmHg) offered no additional benefit and required more vasoactive agents.
The key is identifying the right patient population: chronic hypertensive patients at high postoperative risk undergoing major abdominal surgery, not routine surgical cases.